( http://tscquote.thestreet.com/BBStory.jhtml?tkr=NFLD&id=115944475&src=PRNEWSWIRE
08-28-2001 01:18:35 PM Northfield Laboratories Submits Biologics License Application to FDA For Approval of Its Blood Substitute, PolyHeme(TM)EVANSTON, Ill. Aug. 28 /PRNewswire/ -- Northfield Laboratories Inc.
(Nasdaq: NFLD), a leading developer of an oxygen-carrying blood substitute, today reported that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking approval to market its patented blood substitute product, PolyHeme, as an ideal oxygen-carrying resuscitative fluid for use in the treatment of urgent, life-threatening blood loss."The submission of the BLA for PolyHeme is a significant milestone for
Northfield, and marks a first for a blood substitute for human use in the U.S.," said Richard DeWoskin, chairman and chief executive officer. "PolyHeme provides a remarkable clinical benefit, and represents more than 16 years of product development, clinical studies and data analysis. More importantly, it addresses a large market opportunity and fills an important clinical need."We plan to continue working with the FDA to support the strength of our application and to provide any additional information that may be necessary to achieve a favorable determination," said DeWoskin.
Dr. Steven A. Gould, president, said, "The data from our clinical trials demonstrate that PolyHeme will support life in seriously injured, bleeding patients in the virtual absence of circulating red blood cells, and thereby improve survival in situations when blood cannot be used. We believe these results demonstrate the ability of PolyHeme to effectively and safely transport oxygen. This extraordinary survival benefit indicates that PolyHeme is capable of addressing a critical, unmet medical need, and has led us to file for priority review and fast-track status with the FDA, which we hope will lead to accelerated approval of PolyHeme."PolyHeme is the only blood substitute that has been safely infused rapidly and at large enough dosages to be considered a substitute for acute blood loss in trauma and surgical settings. As a result of the process used to manufacture this product, essentially a solution of polymerized hemoglobin, PolyHeme has a longer shelf life than blood, requires no cross matching and does not transmit disease.
The current market for blood in the United States is estimated to be in the multiple billions of dollars. There were 12.4 million units of blood transfused into approximately 4 million recipients in 1999, according to the latest figures available from the National Blood Data Resource Center. Of that amount, about 2.5 million units are used in urgent, acute blood loss situations -- Northfield's primary focus.
Annual Business Update
The company will provide more detail on its regulatory progress in its
annual business update on August 31, 2001. This presentation will be webcast after the close of the market, at 4:30 p.m. central time, that day. Anyone interested in accessing the presentation should log on to http://www.northfieldlabs.com or http://www.videonewswire.com , or, for those without Internet access, you may dial in to 888-413-4411 to listen to the call. A replay of the webcast will be available for 30 days after the presentation. The telephonic replay will be available for seven days by dialing 888-266-2086 and providing the passcode, 5458560.Northfield's annual meeting will take place earlier that day at 2:00 p.m. central time to vote on business matters as outlined in its August 3rd proxy statement. Only questions related to those business matters will be taken at the meeting. The business update will not be webcast at corporate headquarters......
hawk